Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
RenovoRx Inc(RNXT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RNXT
09/25/2026: RNXT (1-star) is a SELL. SELL for 3 days. Simulated Profits (56.73%). Updated daily EoD!
RenovoRx Inc is a clinical-stage biotechnology company focused on developing catheter-based drug delivery systems for solid tumors. Its primary strength lies in its proprietary TAMP platform, which aims to improve oncology treatment by reducing systemic toxicity. The company's investment story is driven by the potential regulatory success of its lead candidate, RenovoGem. However, as it currently lacks commercial revenue and faces high execution and regulatory risks, it is a speculative stock. It is best suited for growth-oriented investors with a high risk tolerance who are capable of monitoring clinical trial developments and capital needs, rather than those seeking dividends or stability.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers speculative growth potential tied to clinical breakthroughs but lacks current revenue growth metrics. |
| Momentum investor | Mixed fit | Momentum may be driven by clinical trial news, requiring a positive trend signal. |
| Value investor | Weak fit | The lack of earnings and cash flow makes traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and requires capital for development. |
| Low-risk investor | Weak fit | High volatility and the risks associated with clinical development are unsuitable for low-risk strategies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to significant swings based on clinical trial results and financing updates. |
| Valuation risk | High | Valuations are highly speculative as they rely on the potential future success of unapproved products. |
| Competition risk (oncology therapeutics) | High | Large incumbents with superior resources can rapidly shift the standard of care away from RenovoRx's proposed methods. |
| Business quality | Medium | The company has a proprietary platform but lacks the commercial maturity of established biopharma entities. |
| Dividend income | Low / none | The company does not provide income to shareholders. |
| Execution risk | High | Success depends entirely on meeting rigorous clinical endpoints and regulatory requirements. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -57.81% | Avg. Invested days 21 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 74.92M USD | Price to earnings Ratio - | 1Y Target Price 7.12 |
Price to earnings Ratio - | 1Y Target Price 7.12 | ||
Volume (30-day avg) 1.2M shares | Beta 1.12 | 52 Weeks Range 0.70 - 2.59 | Updated Date 09/26/2026 |
52 Weeks Range 0.70 - 2.59 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.31 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancing proprietary RenovoGem and TAMP technology through trial stages. | The company is currently spending money to develop a product, not generating revenue from it. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 64.47M | Price to Sales(TTM) 37.91 |
Enterprise Value 64.47M | Price to Sales(TTM) 37.91 | ||
Enterprise Value to Revenue 32.63 | Enterprise Value to EBITDA -4.72 | Shares Outstanding 45.13M | Shares Floating 39.17M |
Shares Outstanding 45.13M | Shares Floating 39.17M | ||
Percent Insiders 3.6 | Percent Institutions 20.38 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About RenovoRx Inc
Exchange NASDAQ | Headquarters Mountain View, CA, United States | ||
IPO Launch date 2021-08-26 | CEO, Secretary & Director Mr. Shaun R. Bagai | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://renovorx.com |
Full time employees 17 | Website https://renovorx.com | ||
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.